Cancer and venous thromboembolic disease: From molecular mechanisms to clinical management

Current Oncology

Volumn 21, Issue 3, 2014, Pages 134-143

  Donnellan, E ^a   Kevane, B ^a   Healey Bird, B R ^b   Ni Ainle, F ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b BON SECOURS HOSPITAL   (Ireland)

Author keywords

Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANEMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTIVITAMIN K; APIXABAN; CYTOKINE; D DIMER; DABIGATRAN; DALTEPARIN; DEXAMETHASONE; ENOXAPARIN; FONDAPARINUX; LENALIDOMIDE; NADROPARIN; PADGEM PROTEIN; PLACEBO; PROTEIN P53; PROTEINASE; RIVAROXABAN; SEMULOPARIN; THALIDOMIDE; THROMBOPLASTIN; WARFARIN;

AMBULATORY CARE; BLEEDING; CANCER CELL; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CELL SURFACE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERCOAGULABILITY; MEMBRANE MICROPARTICLE; META ANALYSIS (TOPIC); NEOPLASM; NEUTROPHIL; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PREVALENCE; PROPHYLAXIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SURGICAL PATIENT; THROMBOCYTE ACTIVATION; VENOUS THROMBOEMBOLISM;

EID: 84902656922     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.21.1864     Document Type: Review

References (104)

1. Khorana AA. Malignancy, thrombosis and Trousseau: the case for an eponym. J Thromb Haemost 2003;1:2463-2465.
2. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001;102:V215-24.
3. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007;110:1723-1729.
4. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983; 62: 14-31.
5. Prandoni P, Lensing AW, Buller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327:1128-1133.
6. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(suppl):381S-453S.
7. Peuscher FW. Thrombosis and bleeding in cancer patients. Neth J Med 1981;24:23-35.
8. Thompson CM, Rodgers LR. Analysis of the autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the incidence of thromboembolism. Am J Med Sci 1952;223:469-478.
9. Donati MB. Cancer and thrombosis. Haemostasis 1994;24:128-31.
10. Alcalay A, Wun T, Khatri V, et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 2006; 24: 1112-1118.
11. Bullano M F, Willey V, Hauch O, Wygant G, Spyropoulos AC, Hoffman L. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 2005;11:663-673.
12. Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004;164:1653-1661.
13. Prandoni P, Falanga A, Piccioli A. Cancer and venous throm-boembolism. Lancet Oncol 2005;6:401-410.
14. Falanga A, Rickles FR. Pathophysiology of the thrombo-philic state in the cancer patient. Semin Thromb Hemost 1999;25:173-182.
15. Ten Cate H, Falanga A. Overview of the postulated mechanisms linking cancer and thrombosis. Pathophysiol Haemost Thromb 2008;36:122-130.
16. Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb 2006;35:103-110.
17. Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol 2007;62:126-136.
18. Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007;(suppl 1):246-54.
19. Versteeg HH, Peppelenbosch MP, Spek CA. The pleiotropic effects of tissue factor: a possible role for factor viia-induced intracellular signalling? Thromb Haemost 2001;86:1353-1359.
20. Pawlinski R, Mackman N. Cellular sources of tissue factor in endotoxemia and sepsis. Thromb Res 2010;125(suppl 1):S70-S73.
21. van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 2012;119: 924-932.
22. Dorfeutner A, Hintermann E, Tarui T, Takada Y, Ruf W. Cross-talk of integr in α3β1 and tissue factor in cell migration. Mol Biol Cell 2004; 15: 4416-4425.
23. Schaffner F, Versteeg HH, Schillert A, et al. Cooperation of tissue factor cytoplasmic domain and par2 signaling in breast cancer development. Blood 2010;116:6106-6113.
24. Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood 2013;122:1873-1880.
25. Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 1985;24:5558-5567.
26. Kwaan HC. The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 1992;11: 291-311.
27. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004;303:1532-1535.
28. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular dna traps promote thrombosis. Proc Natl Acad Sci U S A 2010;107:15880-15885.
29. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013;13:34-45.
30. Demers M, Krause DS, Schatzberg D, et al. Cancers predispose neutrophils to release extracellular dna traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A 2012;109:13076-130981.
31. Falanga A, Russo L, Verzeroli C. Mechanisms of thrombosis in cancer. Thromb Res 2013;131(suppl 1):S59-S62.
32. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous throm-boembolism among hospitalized cancer patients. Cancer 2007;110:2339-2346.
33. Blom J W, Doggen CJ, Osanto S, Rosendaal FR. Malig nancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715-722.
34. Sallah S, Wan JY, Nguyen N P. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002;87:575-579.
35. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005;104:2822-2829.
36. Park LC, Woo SY, Kim S, et al. Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: results from a prospective cohort study with Asian population. Thromb Res 2012;130:e6-e12.
37. Khorana AA, Francis CW, Menzies KE, et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008; 6: 1983-1985.
38. Starling N, Rao S, Cunningham D, et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fuoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 2009;27:3786-3793.
39. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-815.
40. Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006;4:529-535.
41. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003;21:3665-3675.
42. Bennett CL, Silver SM, Djulbegovic B, et al. Venous throm -boembolism and mortality associated with recombinant eryth-ropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299:914-924.
43. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008;168:2377-2381.
44. Ay C, Vormittag R, Dunkler D, et al. D-Dimer and prothrom-bin fragment 1+2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27:4124-9.
45. Lyman GH, Khorana AA, Kuderer NM, et al. Venous throm -boembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2189-2204.
46. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907.
47. Kakkar A K, Levine M, Pinedo H M, Wolf f R, Wong J. Venou s thrombosis in cancer patients: insights from the frontline survey. Oncologist 2003;8:381-388.
48. Lyman GH, Khorana AA, Kuderer NM, et al. Venous throm -boembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2189-2204.
49. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboem-bolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006;332:325-359.
50. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vait-kus PT, Goldhaber SZ on behalf of the prevent Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874-879.
51. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous th romboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793-800.
52. Khorana AA. The nccn clinical practice guidelines on venous thromboembolic disease: strategies for improving vte prophylaxis in hospitalized cancer patients. Oncologist 2007;12:1361-1370.
53. Amin A, Stemkowski S, Lin J, Yang G. Thromboprophylaxis rates in US medical centers: success or failure? J Thromb Haemost 2007; 5:1610-1616.
54. Burleigh E, Wang C, Foster D, et al. Thromboprophylaxis in medically ill patients at risk for venous thromboembolism. Am J Health Syst Pharm 2006;63(suppl 6):S23-S29.
55. Kahn SR, Panju A, Geerts W, et al. On behalf of the curve study investigators. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res 2007;119:145-155.
56. Seddighzadeh A, Shetty R, Goldhaber SZ. Venous thrombo-embolism in patients with active cancer. Thromb Haemost 2007;98:656-661.
57. Rana P, Levine MN. Prevention of thrombosis in ambulatory patients with cancer. J Clin Oncol 2009;27:4885-4888.
58. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thrombo-embolism in stage iv breast cancer. Lancet 1994;343:886-889.
59. Agnelli G, Gussoni G, Bianchini C, et al. On behalf of the protecht investigators. Nadroparin for the prevention of thromboembolic events inambulator y patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009;10:943-949.
60. Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012;366:601-609.
61. Maraveyas A, Waters J, Roy R, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 2012;48:1283-92.
62. Riess H, Pelzer U, Hilbig A, et al. Rationale and design of prospect-conko 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy. BMC Cancer 2008;8: 361.
63. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003;90:446-455.
64. Huber O, Bounameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg 1992;127:310-13.
65. Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @ristos project. Ann Surg 2006;243:89-95.
66. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-a nalysis of low molecular weight heparin in the pre -vention of venous thromboembolism in general surgery. Br J Surg 2001;88:913-930.
67. Roderick P, Ferris G, Wilson K, et al. Towards evidence-based guidelines for the prevention of venous thrombo-embolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. Health Technol Assess 2005;9:iii-iv, ix-x,1-78.
68. Cardiovascular Disease Educational and Research Trust, Cyprus Cardiovascular Disease Educational and Research Trust, European Venous Forum, International Surgical Thrombosis Forum, International Union of Angiology, and Union Internationale de Phlébologie. Prevention and treatment of venous thromboembolism. International consensus statement (guidelines according to scientifc evidence). Int Angiol 2006;25:101-161.
69. Bergqvist D, Agnelli G, Cohen AT, et al. On behalf of the enoxacan ii investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975-980.
70. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, et al. Prolonged prophylaxis with daltepar i n to prevent late thromboem-bolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 2006;4:2384-2390.
71. Simonneau G, Laporte S, Mismetti P, et al. On behalf of the FX140 study investigators. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. J Thromb Haemost 2006;4:1693-1700.
72. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.
73. Carrier M, Khorana AA, Zwicker J, Noble S, Lee AY on behalf of the Subcommittee on Haemostasis and Malignancy for the ssc of the isth. Management of challenging cases of patients with cancer associated thrombosis including recurrent thrombosis and bleeding: guidance from the ssc of the isth. J Thromb Haemost 2013; 11: 1760-1765.
74. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996;100:269-277.
75. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR. Do heparins do more than just treat thrombosis? The infuence of heparins on cancer spread. Thromb Haemost 1999;82:947-952.
76. Conti S, Guercini F, Iorio A. Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months. Pathophysiol Haemost Thromb 2004;33:197-201.
77. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729-1735.
78. Spirk D, Ugi J, Korte W, et al. Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer. The Swiss Venous Thromboembolism Registry (swivter) ii. Thromb Haemost 2011;105: 962-967.
79. Imberti D, Agnelli G, Ageno W, et al. On behalf of the master investigators. Clinical characteristics and management of cancer-associated acute venous thromboembo-lism: findings from the master Registry. Haematologica 2008;93:273-278.
80. Levine MN. New antithrombotic drugs: potential for use in oncology. J Clin Oncol 2009; 27: 4912-4918.
81. Agnelli G, Buller HR, Cohen A, et al. On behalf of the amplify investigators. Oral apixaban for the treatment of acute venous thromboembolism N Engl J Med 2013;369:799-808.
82. Cohen AT, Spiro TE, Buller HR, et al. On behalf of the magellan investigators. R ivaroxaban for th romboprophylaxis in acutely ill medical patients. N Engl J Med 2013;368:513-523.
83. Bauersachs R, Berkowitz SD, Brenner B, et al. On behalf of the einstein investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-2510.
84. Büller H R, Prins MH, Lensin AW, et al. On behalf of the einstein-peinvestigat or s. Oralrivaroxaba n for t he treatment of symptom-atic pulmonary embolism. N Engl J Med 2012;366:1287-1297.
85. Schulman S, Kearon C, Kakkar AK, et al. On behalf of the re-cover study group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-2352.
86. Van Es J, Eerenberg ES, Kamphuisen PW, Buller HR. How to prevent, treat, and overcome current clinical challenges of vte. J Thromb Haemost 2011;9(suppl 1):265-274.
87. Cunningham MS, Preston RJ, O'Donnell JS. Does antithrom-botic therapy improve survival in cancer patients? Blood Rev 2009; 23:129-135.
88. Casu B, Vlodavsky I, Sanderson R D. Non-anticoagulant hepa-rins and inhibition of cancer. Pathophysiol Haemost Thromb 2008;36:195-203.
89. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;407:258-264.
90. Gleeson EM, O'Donnell JS, Hams E, et al. Activated factor x signaling via protease-activated receptor 2 suppresses pro-inflammatory cytokine production from lipopolysaccharide-stimulated myeloid cells. Haematologica 2014;99:185-193.
91. Liu J, Schuff-Werner P, Steiner M. Thrombin/thrombin receptor (par-1)-mediated induction of IL-8 and vegf expression in prostate cancer cells. Biochem Biophys Res Commun 2006;343:183-189.
92. Morris DR, Ding Y, Ricks TK, Gullapalli A, Wolfe BL, Trejo J. Protease-activated receptor-2 is essential for factor viia and xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res 2006;66:307-314.
93. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000;96:3302-3309.
94. Palumbo JS, Degen JL. Fibrinogen and tumor cell metastasis. Haemostasis 2001;31(suppl 1):11-15.
95. Mousa SA, Petersen LJ. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost 2009;102:258-267.
96. Hostettler N, Naggi A, Torri G, et al. P-selectin- and hepa-ranase-dependent antimet a static activity of non-anticoagulant heparins. FAS EB J 2007;21:3562-3572.
97. Khorana AA, Sahni A, Altland OD, Francis CW. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol 2003; 23: 2110-2115.
98. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L- and P-se-lectin and inhibit acute inflammation. Blood 1993;82:3253-3258.
99. Balzarotti M, Fontana F, Marras C, et al. In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas. Oncol Res 2006;16: 245-250.
100. Li HL, Ye KH, Zhang HW, et al. Effect of heparin on apoptosis in human nasopharyngeal carcinoma CNE2 cells. Cell Res 2001;11: 311-315.
101. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and sur vival in adva nced cancer: the fragmin advanced malignancy outcome study (famous). J Clin Oncol 2004;22:1944-1948.
102. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-2135.
103. Kuderer N M, K horana A A, Lyman GH, Francis CW. A met a-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 2007; 110: 1149-1161.
104. Sideras K, Schaefer PL, Okuno SH, et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 2006;81:758-767.